— ALWAYS EVOLVING — Medium-Term Management Plan For 2017-2019

Teijin Limited February 6, 2017

The New Plan viewed from the Long-term Vision



Long-term Vision

Teijin aims to be an enterprise that is essential to tomorrow's society by continuously creating new value

Medium-term
Management Plan
Policy

Teijin will clarify its action plans for the next three years to realize the longterm vision, in conjunction with working to steadily execute its growth and transformation strategies and strengthen the management system platform supporting those strategies

Change for 2016
Previous Medium-term
Management Plan

- Transformation Of Fundamental Portfolios
- Evolution Toward
 A Solutions-based
 Business Model

Revised Medium-term Management Plan

- Restructuring InitiativesRebuild earnings base
- Transformation and Growth Strategies
 Make intensive investments

New Medium-term Management Plan

Growth Strategies

Further strengthen core earnings power

Transformation Strategies

Establish new core businesses

Strengthen The Management System Platform

EBITDA

Over ¥120 billion

Long-term Vision

An Enterprise that is Essential To Tomorrow's Society

EBITDA
Over ¥200 billion

FY2012

FY2014 - FY2016

FY2017

FY2019



Strategies for Realizing the Long-term Vision

- Growth Strategy
- : Strengthen core earnings power by accelerating growth in existing businesses
- Transformation Strategy
- : Establish new core businesses and transform business models
- **▼** Materials
- Expand to close-to-customer businesses
- **▼** Healthcare
- Diversify product and service lineups and establish cutting-edge business platforms
- Global Strategy
- : Strengthen regional focus in line with business characteristics
- ▼ Composite products
- Expand globally from North America (close to customer)
- Materials supply business
- Expand globally

- ▼ Healthcare
- Focus primarily on Japan (an advanced aging country)

Management Targets

: ROE **10**%+

EBITDA Over ¥120 billion (FY2019)

Resource Allocation

: Capital expenditure + M&A budget ¥300 billion (3-year total)

Strengthen The Management System Platform

Strengthen an effective system underpinning growth and transformation strategies

- Strengthen the Organizational Structure
- Cost Restructuring Initiatives
- Smart Project Promotion
- Diversity Promotion

- Integrate businesses
 /Appoint a Global Strategy Officer and an Information Strategy Officer
 - Achieve cost reduction of ¥20 billion (compared with 2016)
- Creation of new businesses and change in business styles using IT
- Harness and refine human resources



Review of the Previous Medium-term Management Plan

(Revised Medium-term Management Plan in 2014)

Restructuring Initiatives

Dramatic restructuring of unprofitable businesses progressed largely as planned

	FY2015	FY2016	FY2017
Plastics	Shut down Singapore plant Completed	Completed	Specialize in high-value-added
Films	production to Utsunomiva Cor	egrate domestic production overt film business joint venture I Indonesia into wholly owned so	applications s in Japan
Home Healthcare in the U.S.	Streamline operations —	Implement bold reorganization measures	Scheduled for completion
Advanced Fibers	Polyester fibers Successively transfer production to Thailand	Progressing as planned	Close and cease production at certain domestic plants
Raw Materials and Polymerization	Cease DMT production Complete	d Reorganize polymerizati	on plant


Transformation and Growth Strategies


Intensively allocated resources to realize a solutions-oriented business

- \rightarrow Made strategic investments of around ¥100 billion (FY2014-16 total)
- Acquired Continental Structural Plastics (Automotive Components Business)
- Acquired land in the U.S. for a carbon fiber plant
- Founded Teijin Nakashima Medical Co., Ltd. (Artificial Joint Business)
- Established the Technology Integrated Pharmaceutics Center(advanced Medical Materials Business)


Operating Results
Targets (through FY2016)

Consolidated operating income of \$50 billion and ROE of \$%+ \rightarrow Achieved ahead of schedule, in FY2015









Achieved record-high earnings as extraordinary losses subsided

^{*} In these presentation materials, profit attributable to owners of parent is shown as "net income" for the convenience of readers.



Corporate Philosophy and Vision

Corporate Philosophy and Vision



Our Corporate Philosophy

In Harmony with Society

Enhancing the Quality of Life

The Teijin Group's purpose is to enhance the quality of life through a deep insight into human nature and needs, together with the application of our creative abilities **Empowering Our People**

Our Vision

An Enterprise That Is Essential To Tomorrow's Society "QOL Innovator"

- An enterprise that helps to solve social issues
- An enterprise that achieves continuous transformation by anticipating changes in the external environment
- An enterprise that continues to create new value at all times



Our Vision

An enterprise that helps to solve social issues

Social Issues

- Growing severity of environmental problems and stricter environmental regulations
- Heightened interest in safety and security and disaster mitigation awareness
- Progression of demographic change

- Disparity in economic growth on a global level
- Respect for the human rights of workers
- Calls for better corporate governance

The Teijin Group's Strengths

A unique entity with 3 different core business domains



Materials Healthcare IT

Basic technologies for creating new materials and new products

Pharmaceutical development technology, home healthcare networks

IT development technology and expertise straddling

both B2B and B2C fields

Early initiatives for strengthening corporate governance

Identify our Core Priority Fields



Our Core Priority Fields

In order to become a company that is essential to tomorrow's society, Teijin will strive to capture business opportunities leveraging its strengths from the issues facing society, and to strengthen the management base

	Environment	Society	Governance
C	Environmental Value Solutions	Safety, Security and Disaster Mitigation Solutions	
apture Oppor	Contribute by supplying weight- reducing materials that help to enhance the environmental	Help to enhance safety with respect to disaster-readiness measures and social infrastructure development	
apture Busines Opportunities	performance of transportation	Demographic Change And Increased Health Consciousness Solutions	
SSS		Support health maintenance and enhancement in response to the progression of demographic change and the increase in lifestyle diseases	
Strengthen the Management Base	Reducing Environmental Impact	Diversity Promote the success of a wide range of human resources, regardless of gender, nationality or age	 Corporate Governance Ensure the effectiveness of management systems Dialogue and collaboration with stakeholders



Our Vision

An enterprise that achieves continuous transformation by anticipating changes in the external environment

An enterprise that continues to create new value at all times

- •In an increasingly uncertain external environment, we will take the initiative in driving evolution, instead of chasing trends, with a view to achieving sustained growth
- Create products and services that accelerate the evolution of society

Ceaseless Evolution and Ambition "ALWAYS EVOLVING"

Drive sustained growth

by accomplishing business portfolio transformation in tandem with maximizing business opportunities for Teijin

Business Strategies

Business Portfolio Transformation

Current Business Portfolio


High-performance Healthcare Materials

Aramid fibers, carbon fibers and plastics, etc.

Businesses within the scope of public insurance

How We Envision Our Business In 10 Years

With the **MATERIALS** business field and the **HEALTHCARE** business field **as the pillars** of its operations, Teijin will have developed "new businesses that are not yet contributing to profits at present" into core earnings sources, without merely relying on the continuation of existing businesses



Transforming into a business portfolio with new highly profitable businesses at the core

High-performance Healthcare Materials

Integration

Growth Strategy

(existing businesses)

Business Portfolio Transformation



Role of Each Business

Role In Portfolio Transformation	Materials Business Field	Healthcare Business Field	Resource Allocation Policy (Intensive focus, prioritization)
Transformation	Composite Materials and Components Business	New Healthcare Business	Allocate resources preferentially during this medium-term plan period
Strategies Create and expand new	Expand into the Auto Industry	Diversify Product Lineups	Establish investment budget
future core businesses	Expand LiB separators and Membranes	Establish a Cutting-edge Business Platform	(Around ¥300billion over 3 years)
Growth Strategies Secure cash for the creation and expansion of new businesses	Aramid Fibers Carbon Fibers Plastics	Pharmaceuticals Home Healthcare	Allocate the amount of resources needed for stable growth
Growth Strategies	r	т	TOT Stable growth
Change business models	Trading and Retail Polyester Fibers Polyester Film		 Closely examine and select resource allocation Explore business model creation, collaboration with third parties and other initiative

Focus on the Aircraft and Automobile Businesses

	Macro Trends	Aircraft	The number of aircraft produced, centered on smaller aircraft models, will continue to hold steady or increase
		Automotive	Transformation in design philosophy driven by environmental regulations, adoption of EV, and technological innovation
Our Strategy		'	on of the strong yet lightweight high-performance material business, Ils for higher fuel efficiency in line with stricter environmental regulations
	Aircraft	Carbon Fibers	 Intensively allocate resources to intermediate materials (prepreg, etc.) Build a competitive edge by accelerating the expansion of thermoplastic prepreg and the textile prepreg business
		Aramid Fibers	Expand to air freight containers (promote durability and fire resistance)
	Automobile	Aramid Fibers	Expand products to address demands for weight reduction and higher performance, including tire reinforcement materials
		Plastics	Propose weight reduction and design improvements through high-performance compound products

Address Growing Needs for Social Infrastructure

1488				
Saf	Macro Trends	Infrastructure	Increasing demand for disaster mitigation measures and infrastructure development in emerging countries	
etv		Protective clothing	Expansion of demand in Asia and emerging countries due to rising safety standards	
Securit	Our Strategy		dress heightened disaster mitigation awareness and growing needs for anding infrastructure	
Safety. Security and Disaster	Infrastructure	Para-aramid Fibers	Expand sales of optical fiber in China and IndiaApplications such as rope and deep sea oil drilling (Technora)	
isaster		Polyester Fibers Plastics	Develop and expand disaster mitigation applications	
A21V	Protective clothing	Meta-aramid Fibers	Expand the development of textiles for protective clothing primarily to Asia and emerging countries	JE.
Dovels	Carbon Fibers		 Study investment in a new plant in the U.S. 	2
Develo A Grov	•	Aramid Fibers	 Promote high efficiency at existing plants 	
A Growth Platform Materials Business Field		Dolvostor Eibors	_ Strengthen ability to provide solutions through organizational integration	15

HOT

Demographic change and increased health consciousness solutions

Strengthen Growth Domains


	Macro Trends	Pharmaceuticals	Accelerated steps to curb medical costs, and increasingly difficult new drug development
		Home Healthcare	Continued increase in the number of patients. Evolution in patient QOL enhancement services using IoT and other technologies
	Our Strategy	Maximize earnings fro while focusing on drug	m existing growth drivers, g discovery research
	P	Feburic, a treatment for hyperuricemia and gout	Maximize sales by raising disease awareness based on clinical research and boosting recognition of the importance of treatment
	harmace	Pharmaceuticals Pipeline Strategy	■ Expand drug discovery fields Nuclear receptor drug discovery, macrocyclic and constrained peptide drug discovery, advanced medical materials (pharmaceuticals + biocompatible materials)
	uticals		■ Regenerative medicine initiatives Treatment of chronic motor impairments resulting from stroke (SB623), and other treatments for neurological diseases
			■ Maximize value by promoting alliances for products developed in-house
	Ho Healt	CPAP ventilators for the treatment of SAS	Secure high growth by developing relationships with general practitioners, strengthening <i>NemLink</i> functions, and making SAS diagnosis easier
	Home Healthcare	Oxygen concentrator for	Maintain a high market share through such means as supplying next- generation portable models and strengthening monitoring functions for

^{*}The IoT (Internet of Things) is a concept that describes the interconnection of a vast array of devices worldwide via the Internet

signs of exacerbation and other parameters

B) Transformation strategies: Materials Business Field





Automotive Composite Products Business

Macro Trends Continuing trend toward reducing vehicle weight based on environmental regulations Technological innovation will continue to drastically reshape the industrial structure of the auto industry

Our Strategy Rather than merely extending our own materials businesses to downstream fields, we will leverage our strengths in composite technologies to expand business with a view to becoming a multimaterial component supplier

Transform Business Models

 \sim 2016

2017~

Medium to long term

Materials Supplier

Tier 1 Components

Manufacturer

Component Supply Partner (With design ability)

Supply materials to Tier 1 manufacturers

Provide a stable supply of components to automakers

Provide comprehensive vehicle-weight reduction, multi-material use and other proposals

Acquisition of CSP

A Tier 1 manufacturer with multiple channels to major automakers





Lithium-ion Battery (LiB) Separator and Membrane Business

Macro Trends

Growing demand for LiB separators in step with expansion of the markets for LiB for consumer electronics and automotive use

Our Strategy Beginning with technologies and expertise developed in membrane production, we will roll out products that achieve both high performance and high productivity in a wide range of fields

Double-sided coating technology for microporous membranes

LIELSORT
LIB separator

Further expand applications as a leading coated-separator company

From supplying materials to the filter business

Expand consumer electronics applications





Large Storage Battery, Battery Management Systems

Our Membrane Technology

hnology

Control technology for membrane thickness, pore size, and porosity miraim


high-performance microporous membrane Apply for use in semiconductor filters

Heat exchange membranes, Fuel cells

Membranes For Medical Devices

B) Transformation strategies: Healthcare Business Field






Macro Trends Faced with a challenging environment for curtailing medical expenses and the increasing difficulty of discovering new drugs, new business opportunities are emerging against the backdrop of advances in comprehensive community healthcare systems and the penetration of IT.

Our Strategy Provide comprehensive healthcare services encompassing non-insurance business fields by strengthening the existing healthcare business platform, without restricting ourselves to existing insurance-based healthcare services.

Diversify product and service lineups



Establish A Cutting-edge Healthcare Business Platform

Work to establish a healthcare business platform supporting pre-symptomatic conditions, diseases, and nursing care in their entirety, and to create new businesses harnessing information

platforms

<Our Business Fields>

Diseases

Develop and introduce new products and services

Orthopedic Implantable Devices

New Medical Products

Pre-Symptomatic Conditions (Current)
Pharmaceuticals,
medical products
& IT services

Nursing Care

Digital Healthcare

Functional Food Material Commence the health promotion business

Provide nursing care IT service businesses

<Establish a Cutting-edge Business Platform>

We work to Strengthen;

- **■** Home Healthcare Services
- Expand the introduction of community healthcare network systems
- Apply AI to home healthcare call centers, and ensure all our medical products are IoT enabled

■ Healthcare R&D

- Allocate R&D resources to home healthcare, implantable products, pre-symptomatic conditions diagnosis and health promotion
- Establish healthcare data platforms


■ Our healthcare business platform with a history of over 40 years ■ R&D capabilities in both pharmaceuticals and medical products ■ Home healthcare services with a top domestic share

Home Healthcare :Bolster the services network in Japan
 New Non-insurance Business : Establish business model in Japan, and Set sights on overseas expansion in future

- Execute regional strategies based on the characteristics of each business in line with growth and transformation strategies.
- Strengthen regional management structures straddling businesses (appoint a Global Strategy Officer)
 Work to develop systems to efficiently manage overseas businesses and formulate regional strategies

Expand Globally Closer to Customers Materials Supply Businesses Composite Products Business (Auto & Aircraft) Cultivate demand globally, on the basis of customers Promote development and expand business by and regions that have highly commended constantly anticipating needs, while closely approaching the properties of our materials key customers in each region Cultivate demand in emerging countries and other Automobiles : Expand globally from North America markets by honing our cost competitiveness, in tandem (expand the components business) with conducting optimal production in terms of location Aircraft : Europe and the Americas and scale. (Secure an intermediate materials production site) **Advanced Aging Country Healthcare business** Expand business according to regional characteristics (pharmaceutical jurisprudence, medical fees, etc.) ■ Pharmaceuticals: Maximize the business in Japan, strengthen exports and licensing








Strengthen the Management System Platform



Evolving into an organization that accelerates growth/transformation strategies

- Restructuring of Organizational Structure
- •Inter-business integration will be promoted by integrating materials-related businesses into the materials business
- Coordination will be deepened by splitting up the New Business Development
 Business Unit into materials and healthcare business
- Global Strategy Officer
- : Promote regional strategies across businesses
- Information Strategy Officer: Promote smart projects on a Group-wide basis





Proactively capture and utilize IT as it evolves exponentially, in order to achieve the creation of new businesses and change in business styles.

Future Trends

- Penetration of digitalization
- Further evolution of Al

Objectively capture / harness

advances in technology

- Widespread adoption of IoT (Internet of things)
- Advances in robotic engineering

Medium-term Actions and Targets

Expand Healthcare Services

Expand various services based on information platforms Convert to AI-based contact centers

Convert to automated processes Visualize production processes and improve productivity

Operating Process

Digitalization of business processes and databasing

Current Initiatives

- Healthcare Monitoring systems for home healthcare devices (NemLink) Construct information platform(VitalLink)
- **Materials** Utilize IoT technology to improve productivity (started at certain plants)
- IoT activity trial, app development, Al research

Capture business opportunities / possibilities

Convert to smart plants

Innovation

Develop next-generation information infrastructure and tools



Benefits of Cost Restructuring Initiatives:

Target cost benefits of **¥20** billion by FY2019 (compared with FY2016)

Restructuring Initiatives + Strengthening Product Cost Competitiveness: \$11 billion

Restructuring Initiatives

: Benefits fully realized by completing measures in the revised medium-term management plan in 2014

- ▼Complete bold reorganization measures for home healthcare business in U.S. and the reorganization of plants in the domestic films business in FY2016
- ▼ Steadily pushing ahead with the transfer of polyester fibers production to Thailand and the reorganization of polymerization plant; planned for completion within FY2017

Competitiveness

Strengthen Product Cost : Pursue productivity enhancements centered on growth businesses

▼ Aramid Fibers : Automation and deployment of multiple spinning production processes

V Carbon Fibers : Boost energy efficiency

▼ Home Healthcare: Rationalize ancillary costs by launching new models of equipment

Head Office Restructuring Initiatives: ¥9 billion

Restructuring into a "Small Head Office" commensurate with business scale after the implementation of restructuring initiatives

- ▼ Enhance marketing efficiency and rationalize administrative divisions through business integration (streamline organization, centralize operations)
- Develop information infrastructure to enhance productivity, digitalize functions/work

Management Targets

Financial Indicators



New key performance indicators will be established with an emphasis on both **investment efficiency** and **earnings power**

Profitability Indicators

Most Important Indicators

Growth Indicators

ROE

Investment returns on funds entrusted by shareholders

Group-wide

EBITDA

Ability to generate cash to fund growth investment and shareholder returns

Group-wide and For Each Business

Secure Growth

Based on individual business activities, work to improve indicators on a Group-wide basis

Pursue


Efficiency

ROIC

based on operating income

Efficiency of generating profits relative to capital invested in business activities

Group-wide and For Each Business





ROE based on net income > 10%+ = Ensure stable profits

Break free from the low profit structure of the past by enhancing the profitability of each business and transforming the portfolio, generating stable shareholder returns exceeding the cost of shareholders' equity (7-8%)




ROIC based on operating income > 8%+ = Pursue investment efficiency



EBITDA > Generate more than **¥120** billion = Increase ability to generate cash

Secure the earnings power needed to fund growth investments and provide shareholder returns, as the source of corporate value





Original KPIs will be set, including non-financial information, to **visualize and monitor business portfolio transformation**, with follow-up on progress

Net Sales from Transformation Strategy Projects

Create new businesses and accelerate their growth

Business expansion through the promotion of transformation strategy

- Materials business: Accelerate expansion to close-to-customer businesses
- Healthcare business: Create new businesses using cutting-edge healthcare business platforms

Degree of Diversity Promotion

Enhance competitiveness
by harnessing and
refining human
resources

Penetration of diversity and workstyle reforms

- Harness and nurture diverse human resources
 Promote the success of human resources regardless of gender, nationality, experience and sense of values
- Promote workstyle reforms

Promote the design of systems to support diverse workstyles in step with the times, in addition to existing systems such as telework and "Hello Again" programs*

Resource allocation and shareholder returns



Policy on Resource Allocation

Capital Expenditure + M&A Budget : ¥300 billion (3-year total)

Capital Expenditure: allocate 50%+ to growth and transformation strategies

Growth Strategy Investments

Construct a new carbon fiber plant, invest in healthcare systems, etc.

Transformation Strategy Investments

Composite materials, LiB separators and membranes, orthopedic implants

M&A

: Proactively make use of external resources in the course of executing transformation strategies

■ R&D Expenses : Targeting around 5% of net sales

Development budget related to transformation strategies

: secure approx. **30**% of R&D expenses (3-year total)

Shareholder Return Policies

- Adopt a basic policy of paying dividends in line with consolidated operating results, targeting a consolidated dividend payout ratio of 30% for the medium term.
- Determine dividends by giving consideration to the need to ensure financial soundness, to our ability to maintain stable dividend payments over the medium to long term and to securing sufficient internal reserves to fund strategic investments aimed at ensuring future growth.



Disclaimer

Any statements in this document, other than those of historical fact, are forward-looking statements about the future performance of Teijin and its Group companies, which are based on management's assumptions and beliefs in light of information currently available, and involve risks and uncertainties. Actual results may differ materially from these forecasts.

Business Risks

The Teijin Group recognizes certain risks as having the potential to affect its operating results and/or financial position. As of the date of this document, these risks included, but were not limited to, the risks listed below.

(1) Market-related risk

The Teijin Group manufactures and sells products, the sales of which may be affected by market conditions, competition with other companies and price fluctuations arising thereof, as well as fluctuations in raw materials prices and fuel costs, and such market factors as fluctuations in foreign exchange and interest rates.

(2) Product quality risk

The Teijin Group has established a dedicated division that is charged with product quality and reliability assurance for all Group businesses. However, product and service defects arising from quality issues have the potential to negatively affect, among others, the Group's operating results, financial position and public reputation.

(3) R&D-related risk in the pharmaceuticals business

The Teijin Group actively allocates management resources to R&D efforts. R&D in the pharmaceuticals business, in particular, is characterized by significant investments of funds and time. Pharmaceuticals discovery research has a high incidence of failure to discover promising drugs. There are also risks that plans to apply for regulatory approval may be abandoned or that approval may be rescinded.

(4) Risks related to overseas operations

The Teijin Group has operations overseas. These operations are vulnerable to the impact of fluctuations in foreign exchange rates, as well as enforcement of new or unexpected changes to existing laws, regulations or tax systems that exert an adverse impact on the Group; economic fluctuations; or social unrest triggered by acts of terror or war.

(5) Risks related to accidents and disasters

In the event of a major natural disaster or unforeseen accident that results in damage to the Teijin Group's production facilities or significantly impedes the Group's supply chain, such developments may have a negative impact on the Group's operating results and/or financial position.

Italicized product names and service names in this report are trademarks or registered trademarks of the Teijin Group in Japan and/or other countries. Where noted, other italicized product names and service names used in this document are protected as the trademarks and/or trade names of other companies.

Reference Materials

Aiming for the sustainable development of our business and society, The Teijin Group identified the following materiality for a variety of issues related to corporate social responsibilities, and is advancing CSR management that is integrated with our business strategies.

		Environment	Society	Governance
Core Priority Fields (Medium-term management	Capture Business Opportunities	■ Environmental value solutions	 Safety, security and disaster mitigation solutions Demographic change and increased health consciousness solutions 	
plan)	Strengthen the Management Base	Reducing environmental impact	■ Diversity	■ Corporate governance
Fields Requiring Continuing Efforts	Enhance the Management Base	Conservation of biodiversity	 Information security Product liability/ Quality assurance Disaster prevention Occupational safety 	Corporate ethics and complianceCSR communication
			and hygiene ■ CSR procurement	(


Corporate governance system



Set up an Advisory Board with a majority of outside experts to ensure highly transparent management (from 1999)

Efforts were made to further enhance transparency with respect to executive personnel through a Nomination Consultation Committee and a Remuneration Consultation Committee

Implementing integrated management of business operating risks and management strategy risks through





- Step up the promotion of workstyle diversity, women's advancement, and personnel diversity more than ever, aiming for an organization that demonstrates the abilities of diverse human resources with different values and experiences, in order to revitalize the organization and stimulate innovation.
- To this end, we will set KPIs from many different perspectives, in addition to the disclosure of indicators* that are already at a high level. We will also promote and follow-up on human resources utilization directed at achieving these targets.

Degree Of Diversity Promotion, examples of indicators (goals to be achieved in 10 years)

Basic Approach	Diversity recognition rate 100%
Diverse Workstyles	Work-at-home system utilization rate 50%
	Number of female executives 10+
Women's Advancement	Managerial positions (Japan) 3 times more female managers than now (Overseas) Ratio of female managers 33%
Personnel Diversity	Number of foreign-national executives 12+

^{*}e.g.)Current disclosure of indicators(Japan): Average overtime per month for employees, Ratio of annual taken paid holidays,
Return to work rates after parental leave, Average years at company by gender,
Ratio of newly recruited career-oriented female university graduates

Reducing Environmental Impact



The Teijin Group is working to reduce environmental impact over the entire life cycle of products, including all processes from material procurement to production, use and disposal

(Environmental impact reduction targets) (established in FY2010)

Greenhouse Gas Emissions from **Manufacturing Operations**

Emissions of Chemical Substances into the Environment

Waste with No Effective Use

Achieve a CO2 emissions reduction ratio of 1% or more per year (compared to the level in fiscal 2011)

By fiscal 2020, reduce by 80% or more compared to fiscal 1998 level

Reduce "waste with no effective use" by 85% or more compared to the fiscal 1998 level by fiscal 2020

[Environmental Impact during Manufacturing in FY2015 by Input / Output]

INPUT

Energy* 28.3×10^{6}

Chemical substances handled


0.654 million tons

Freshwater consumption

83 million tons

Seawater consumption

39 million tons



OUTPUT CO^2 **Average annual reduction** 1.80 million tons of 5% compared to FY2011 Chemical substances Reduced by 78% compared to FY1998 level 1,956 tons Waste with no effective use Reduced by 94% compared to FY1998 level 2,978 tons Water discharged 111 million tons



Human Chemistry, Human Solutions

The promise of the Teijin brand is summed up in the resonant statement: "Human Chemistry, Human Solutions".

Our promise is to continue to develop chemical technologies that are friendly to both people and the global environment. It is to keep providing solutions that deliver the real value that society and our customers expect.

We will certainly keep this promise. Constantly working to enhance the Quality of Life -our very reason for being as a company- the Teijin Group will continue to win the trust of society and our customers.